ArticleACG case reports journal2026
A Novel Use of Tenapanor in Patients With Hepatic Encephalopathy: A Case Series.
Article in ACG case reports journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic encephalopathy (HE) is often inadequately managed by standard therapies (lactulose and/or rifaximin). This case series presents 5 patients with decompensated cirrhosis and HE who received tenapanor (50 mg once or twice daily) due to inadequate response to standard therapies. Outcomes included bowel movement frequency, HE symptom improvement, and safety. Four patients showed improved bowel frequency, stool consistency, and HE severity. HE recurred in 3 patients after discontinuation. Tenapanor was well-tolerated, with mild, self-resolved dehydration in one case. Patients preferred tenapanor for taste and dosing convenience over lactulose. The findings suggested that tenapanor may alleviate HE with high safety and compliance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.